Close
Sukeshi Arora, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Sukeshi Arora, M.D.
Dr. Arora received her medical degree from UT Southwestern Medical School in Dallas. She completed an internal medicine residency and hematology oncology fellowship at the University of Texas Health Science Center San Antonio. After graduation, she joined as faculty at UT Health San Antonio and leads the gastrointestinal malignancies program as well as the geriatric oncology program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson. Her research interests are drug development for new treatments for hepatobiliary cancers and pancreatic cancers as well as improving the care for older adults with cancers. She is also a faculty member for the cancer genetics and high-risk screening clinic.
Gender
- Female
Languages Spoken
- English
- Spanish
- Hindi
- Gujarati
-
Credentials
Credentials
Positions
- Associate Professor of Medicine, University of Texas Health Science Center San Antonio
- John Eiler Endowed Professorship in Cancer Research
Certifications
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- American Board of Internal Medicine, Hematology
Education
- Medical School: University of Texas Southwestern Medical School, Dallas, TX
- Residency: University of Texas Health Science Center San Antonio, San Antonio, TX
- Fellowship: University of Texas Health Science Center San Antonio, San Antonio, TX
-
Locations & Contact
Locations & Contact
She is very compassionate and really listened to my concerns.
Patient
-
Research & Publications
Research & Publications
View all research & publications - Sukeshi Arora, M.D.
-
Clinical Trials
Clinical Trials
Type of Cancer
Colon
ClinicalTrials.gov Identifier
NCT02891538
Principal Investigator
Sukeshi Arora M.D.
A Pilot Study to Evaluate the Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal cancer (CRC) Patients with Curative Resections.
This will be a randomized, controlled pilot trial of patients with histological documentation of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancer. If patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, then the patient is eligible. All eligible subjects will be consented prior to surgery.
Type of Cancer
Liver
ClinicalTrials.gov Identifier
NCT03037437
Principal Investigator
Sukeshi Arora M.D.
Modulation of Sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer (CTMS# 16-0076)
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
ClinicalTrials.gov Identifier
NCT01150045
Principal Investigator
Sukeshi Arora M.D.
CALGB-80702: A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant FOLFOX Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer (CTMS# 14-2011)
PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery. RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways…
ClinicalTrials.gov Identifier
NCT01349881
Principal Investigator
Sukeshi Arora M.D.
S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colo
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Type of Cancer
Liver
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Arora M.D.
Characterizing disease biology, treatment patterns and toxicity in older adults with advanced hepatocellular carcinoma (CTMS# 19-0010)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Arora M.D.
S1815, A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (CTMS# 19-0084)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Arora M.D.
Phase I study of TTI-101, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with advanced cancers. CTMS#: 21-0019
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Arora M.D.
daNIS-3: An Open-Label, Multi-Center, Phase II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With Standard of Care (SOC) Anti-Cancer Therapy for the Second Line Treatment of Metastatic Colorect
This study evaluates the preliminary efficacy and safety of NIS793 and other novel investigational combinations with SOC anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of metastatic colorectal cancer.
Type of Cancer
Liver and Hepatobilary Cancer
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Arora M.D.
Protocol 10476: A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers (CTMS# 22-0023)
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery (unresectable).
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Arora M.D.
Biomarker development for predicting immune checkpoint therapy efficacy of hepatocellular carcinoma (CTMS# 22-0050)
We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study.